Advances in High-Grade Serous Ovarian Cancer: New Perspectives Promising Hope for Eradicating a Devastating Disease
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".
Deadline for manuscript submissions: 31 May 2026 | Viewed by 14
Special Issue Editor
Interests: ovarian cancer; drug repurposing; ovarian cancer development; immunogenic cell death; ER stress
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
I am pleased to invite you to submit original research articles and reviews in the field of high-grade serous ovarian cancer. Ovarian cancer remains a leading cause of cancer-related deaths worldwide. Within the histotypes of ovarian cancer, high-grade serous is the most common and aggressive form, accounting for approximately 70-75% of all ovarian cancer cases, often originating in the fallopian tubes and characterized by rapid progression and poor prognosis. This disease is habitually diagnosed at an advanced stage due to vague symptoms. Treatment usually involves a combination of surgery and chemotherapy with platinum derivatives. This therapy is initially often efficient. However, the disease almost always relapses with a platinum-resistant phenotype (also known as platinum-resistant ovarian cancer or PROC). Once they develop PROC, patients receive therapies that are poorly effective, leading to a median overall survival of only 12 months. This Special Issue intends to bring to the readers novel information related to risk factors, prevention, symptoms, screening, early diagnosis and management, epidemiology, optimization of standard of care, recurrent platinum-resistant disease management, novel therapeutic approaches including repurposed drugs and vaccines, use of artificial intelligence for diagnosis and treatment, life expectancy, quality of life, and prognosis. The overall survival rate of the disease is very poor, with only about 30% of women surviving five years after diagnosis. Consequently, there is an urgent need to develop tools for better disease prevention, early detection, new maintenance therapies to keep the tumours dormant after initial successful chemotherapy, and effective therapies to re-sensitize PROC to chemotherapy. With the development of new technologies worldwide, there is hope to significantly improve the five-year survival rate of this devastating disease and promise to eventually cause its eradication.
I look forward to receiving your contributions,
Prof. Dr. Carlos M. Telleria
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- high-grade serous ovarian cancer
- risk factors
- prevention
- early detection
- symptoms
- screening
- standard of care
- platinum resistant ovarian cancer
- novel therapeutic approaches
- drug repositioning
- artificial intelligence
- life expectancy, quality of life, and prognosis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
